Biomica develops microbiome-based therapeutics using a proprietary computational platform that integrates metagenomics sequencing and AI to identify optimal microbial candidates for treating cancer, immune-mediated, and infectious diseases. The company addresses the challenge of unmet medical needs by maximizing therapeutic efficacy while minimizing adverse effects through carefully curated microbial consortia.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including cancer, immune-mediated disorders, and infectious diseases, lack effective treatments with minimal adverse effects. Current therapeutic approaches often fail to fully address the complex interplay between the human microbiome and disease pathology. There is a need for more targeted and efficacious therapies that harness the therapeutic potential of the microbiome.
Solution
Biomica is a clinical-stage biopharmaceutical company developing microbiome-based therapeutics using a computational platform that integrates metagenomics sequencing and artificial intelligence. The company's proprietary platform, PRISM, leverages big data and advanced AI capabilities to identify and design optimal microbial consortia. By focusing on the functional elements of the microbiome, Biomica selects a minimal number of microbial candidates to maximize beneficial effects while minimizing potential adverse effects. This approach enables the development of novel solutions for complex host-microbiome interactions and facilitates clinically relevant predictions for treating a range of diseases.
Target Audience
Biomica's primary target audience includes patients suffering from cancer, immune-mediated disorders, and infectious diseases, as well as pharmaceutical companies seeking innovative therapeutic solutions.
Features
- PRISM: A proprietary computational platform integrating advanced AI, big data, and a comprehensive database for microbiome analysis.
- Metagenomics sequencing for high-resolution taxonomy and functional profiling of the human microbiome.
- Identification of minimal microbial consortia to maximize therapeutic efficacy and minimize adverse effects.
- Pipeline of drug candidates targeting cancer, immune-mediated disorders, and infectious diseases.